Capital Performance Advisors LLP Summit Therapeutics Inc. Transaction History
Capital Performance Advisors LLP
- $325 Million
- Q3 2024
A detailed history of Capital Performance Advisors LLP transactions in Summit Therapeutics Inc. stock. As of the latest transaction made, Capital Performance Advisors LLP holds 36 shares of SMMT stock, worth $683. This represents 0.0% of its overall portfolio holdings.
Number of Shares
36Holding current value
$683% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding SMMT
# of Institutions
146Shares Held
66.2MCall Options Held
1.05MPut Options Held
1.02M-
Baker Bros. Advisors LP New York, NY23.2MShares$441 Million2.41% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.82MShares$167 Million0.0% of portfolio
-
Black Rock Inc. New York, NY7.9MShares$150 Million0.0% of portfolio
-
State Street Corp Boston, MA4.12MShares$78.3 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA2.96MShares$56.3 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $3.82B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...